Japanese pharma company Eisai (ESAIY) reported positive results in clinical trials of its Alzheimer’s drug Leqembi. This could mean a revolution for administering the drug, which is currently ...
Modeling suggests monthly maintenance dosing will keep biomarkers flat. Several talks showed how fluid biomarkers rebound after patients stop taking the drug. Likewise, cognitive decline returned to ...
Lecanemab authorised in Great Britain and EU re-examination in progress Events during the second quarter 2024 BioArctic and Eisai entered into a research evaluation agreement regarding the drug candid ...
(1) Class of shares to be acquired: Ordinary shares of the Company (2) Total number of shares to be acquired: 6,500,000 shares (maximum) (Ratio to total number of issued shares (excluding treasury ...
6d
News Letter on MSNWhat are the symptoms and treatments for Alzheimer’s – as new drug is rejectedThe NHS spending watchdog says a drug which has showed signs of slowing the progression of Alzheimer’s disease should not be ...
Here's How Much a $1000 Investment in Catalyst Pharmaceutical Made 10 Years Ago Would Be Worth Today
For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and ...
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...
The company has been seeking to test Keytruda in combination with other treatments and expand its use in types of cancers not ...
The market for obesity treatment is expected to expand more than fifteenfold by 2030 due to escalating competition, fueled by ...
Eisai said in a statement that it has set up a company-wide task force to mitigate the situation, and is working on recovery with its cybersecurity partners, as well as talking to law enforcement.
The US Food and Drug Administration (FDA) has granted fast track designation to Life Molecular Imaging’s (LMI) tau positron emission tomography (PET) imaging diagnostic, PI-2620.
Data scientists and clinical researchers will use brain scans from the entire Scottish population to build a software tool ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results